<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="UTF-8">
        <meta name="apple-mobile-web-app-capable" content="yes">
        <meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
        <meta name="apple-mobile-web-app-title" content="AstraZeneca Oncology">
        <link rel="stylesheet" href="css/style.css" />
        <link rel="stylesheet" href="css/fonts.css" />
    <style type="text/css">

        .feature{
            position:absolute;
            top:126px;
            left:40px;
        }

        .feature > ul{
            margin-top:20px;
        }

        .feature li{
            font-size:21px; 
            line-height:26px;
        }

       .feature li:before{
            content:'•';
            display: inline-block;
            color:#e9167d;
            border-radius: 100%;
            position:relative;
            left:-5px;
        }

        .feature li.small{
            font-size:17px;
            line-height:22px;
            margin-left:20px;
            margin-bottom:10px;
            margin-top:5px;
        }

        .graph{
            display:block;
            width:845px;
            height:402px;
            margin-top:-10px;
            margin-left:80px;
            background:url('img/graphs.png') no-repeat;
            background-size:100% auto;
            image-rendering:-webkit-optimize-contrast;
        }

        .feature.f2 .graph{
            background-position-y:-408px;
        }

        .button{
            position:absolute;
            top:433px;
            left:43px;
            width:50px;
            height:115px;
            background:url('img/slider.png');
            background-size: 100% auto;
            -webkit-transition: background-color 0.5s;
            transition: background-color 0.5s;
        }
        
        .button .circle{
            left:0px;
            height:45px;
            width:50px;
            position:relative;
            display:inline-block;
            background:inherit;
            background-position-y:-283px;
            background-color: transparent;
            -webkit-transition: top 0.5s;
            transition: top 0.5s
        }

        .button .text{
            font-family: 'SerifaStd-Bold';
            font-size:15px;
            color: white;
            position:absolute;
            left:10px;
            -webkit-transition: top 0.5s;
            transition: top 0.5s
        }
        
        .container.f1 .button{background-color: #6b5f8a}
        .container.f1 .circle{top:2px;}
        .container.f1 .button .text{top:70px;}

        .container.f2 .button{background-color: #ef0085}
        .container.f2 .circle{top:68px;}
        .container.f2 .text{
            top:35px;
            left:15px;}

        .footnote{
            font-family: 'HelveNeuLigCon';
            position:absolute;
            top:auto;
            bottom:55px;
            left:160px;
            color: #4D4D4D;
            font-size:12px;
        }

        span.study{
            position:absolute;
            top:auto;
            bottom:47px;
            left:100px;
            width:30px;
            height:30px;
            background:url('img/info.png') no-repeat;
            background-size:100% auto;
            image-rendering:-webkit-optimize-contrast;
        }

        span.study:active{
            bottom:45px;
        }

        div.study p{
            width:436px;
        }

        .zoladex div.study{
            line-height: 17px
        }

        
    </style>
    </head>
    <body class='zoladex'>
        <div class="container f1" >
            <span class='logo'></span>
            <span class='footer'></span>
            <span class='ref'></span>
            <span class='pi'></span>
            <span class='study'></span>

            <div class='feature f1''>
                <h2>Zoladex<sup>®</sup> is as effective as CMF* chemotherapy for disease-free survival (DFS)<br />in ER+ early premenopausal breast cancer<sup>1,2</sup></h2>
                <ul>
                    <li>In ER positive, pre and perimenopausal patients (at a median follow-up of 7.3 years)<sup>2</sup></li>
                    <li>Disease-free survival was equivalent between Zoladex and CMF<sup>*2</sup></li>
                    <li class='small'>HR=1.05; 95% CI:0.88–1.24; P=0.597<sup>2</sup></li>
                </ul>
                <span class='graph'></span>
            </div>

            <div class='feature f2 hide'>
                <h2>Zoladex<sup>®</sup> is as effective as CMF* chemotherapy for overall survival (OS) in ER+ early premenopausal breast cancer<sup>1,2</sup></h2>
                <ul>
                    <li>In ER positive, pre and perimenopausal patients (at a median follow-up of 7.3 years)<sup>2</sup></li>
                    <li>Overall survival was non-inferior to CMF*<sup>2</sup></li>
                    <li class='small'>HR=0.94; 95% CI:0.75-1.18; P=0.622<sup>2</sup></li>
                </ul>
                <span class='graph'></span>
            </div>

            <div class='button'>
                <span class='text'>DFS</span>
                <span class='circle'></span>
            </div>

            <p class='footnote'>*cyclophosphamide, methotrexate and fluorouracil</p>

            <div class='ref'>
                <p>References:</p>
                <ul>
                    <li>Jonat W et al. <em>J Clin Oncol</em> 2002;20(24):4628-35</li>
                    <li>Kaufmann M et al. <em>Eur J Cancer</em> 2003;39:1711-1717</li>
                    <li>De Haes H et al. <em>J Clin Oncol</em> 2003;21(24):4510-4516</li>
                </ul>
            </div>

            <div class='study'>
                <p>Study Design (ZEBRA study<sup>1,2</sup>)<br />
                    International, multicentre, open, randomised study in premenopausal patients with node-positive early breast cancer.<br /> 
                    After local therapy for breast cancer (mastectomy or breast-conserving therapy with or without radiotherapy, according to local practice), patients were randomised in a 1:1 ratio to receive goserelin 3.6mg every 28 days for 2 years or 6 x 28 day cycles of CMF chemotherapy (cyclophosphamide 500mg/m<sup>2</sup> intravenously (IV) on days 1 and 8, or 100mg/m<sup>2</sup> orally on days 1 through 14, methotrexate 40mg/m<sup>2</sup> IV on days 1 and 8 and fluorouracil 600mg/m<sup>2</sup> IV on days 1 and 8)<br />
                    The primary efficacy parameters were disease-free survival (DFS) and overall survival (OS).<br />
                    Safety was assessed by overall therapy tolerance and the occurrence of adverse events.
                </p>
            </div>

        </div>
    <script src="js/jquery-1.11.0.min.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/touchy.js" type="text/javascript" charset="utf-8"></script> 
    <script src="js/script.js" type="text/javascript" charset="utf-8"></script>
    <script>
        $(document).ready(function(){

            $('.button').on('tap', function(){
                if($('.container').hasClass('f1')){
                    $('.container').removeClass('f1').addClass('f2');
                    $('.button .text').html('OS')
                    $('.f1').fadeOut();
                    $('.f2').fadeIn();
                }
                else{
                    $('.container').removeClass('f2').addClass('f1');
                    $('.button .text').html('DFS')
                    $('.f2').fadeOut();
                    $('.f1').fadeIn();
                }
            })


        });
    </script>
    </body>
</html> 